Drugs /

ytb323

Back to Drugs List

Overview

Clinical Trials

View Clinical Trials for ytb323

Ytb323 has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating ytb323, 1 is phase 1 (1 open).

CD19 Expression is the most frequent biomarker inclusion criterion for ytb323 clinical trials.

Acute lymphoblastic leukemia, chronic lymphocytic leukemia, and diffuse large B-cell lymphoma are the most common diseases being investigated in ytb323 clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Ytb323
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating ytb323 and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Drug Target(s) [2]:
CD19

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.